Profile picture

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)
Membership: FESC Member
Follow
Biography
Lars Rydén, Senior Professor of Cardiology at the Karolinska Institute, Sweden, specialised in internal medicine and cardiology. His research focus on arrhythmias, cardiac pacing, heart failure and diabetes-related cardiovascular disease. He published more than 700 artticles. He is Dr h.c. at Katowice University, Poland, and an honorary member of the Royal College of Physicians, UK and served as the President of the Swedish Cardiac Society and chaired the Scientific Board of the Swedish Heart Lung Foundation. He was the President of the European Society of Cardiology (ESC), and member of the board of World Heart Federation. He chaired numerous expert groups in collaboration with the ESC and European Commission and the group that produced the European Heart Health Charter and The Chronic Disease Alliance – A Unified Prevention Approach. Professor Rydén chaired the Task Forces of the 2007 and 2013 ESC/European Association for the Study of Diabetes (EASD) Guidelines for Diabetes.
Logo ESC

Contributor content

It is better to invest in health than to pay for disease
Session
It is better to invest in health than to pay for disease
14 April 2023
Diabetes and heart failure: a complex relationship
Session
Diabetes and heart failure: a complex relationship
3 September 2019
Improving cardiovascular risk in patients with obesity
Session
Improving cardiovascular risk in patients with obesity
3 September 2019
Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
Session
Multi-dimensional glucagon-like peptide-1 receptor agonists — Positioning their role in treatment of type 2 diabetes and cardiovascular disease
1 September 2019
The right glucose-lowering drugs for the right patient
Session
The right glucose-lowering drugs for the right patient
31 August 2019
How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?
Session
How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?
27 August 2018
Diabetes for the Cardiologist: integrated Cardio-Metabolic Care of Tomorrow
Session
Diabetes for the Cardiologist: integrated Cardio-Metabolic Care of Tomorrow
26 August 2018
Heart failure and diabetes: a treacherous combination
Session
Heart failure and diabetes: a treacherous combination
29 August 2017
GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?
Session
GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?
28 August 2017
Treatment of type 2 diabetes - Important new aspects for the cardiologist
Session
Treatment of type 2 diabetes - Important new aspects for the cardiologist
27 August 2017

ESC 365 is supported by